Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
about
Sulphonylurea monotherapy for patients with type 2 diabetes mellitusSulphonylurea monotherapy for patients with type 2 diabetes mellitusAlpha-glucosidase inhibitors for type 2 diabetes mellitusThe investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.Changes of fermentation pathways of fecal microbial communities associated with a drug treatment that increases dietary starch in the human colon.Effects of current therapeutic interventions on insulin resistance.Approaches to preventing mealtime hyperglycaemic excursions.The BBZDR/Wor rat model for investigating the complications of type 2 diabetes mellitus.Type 2 diabetes mellitus: a review of current trendsCritical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: a systematic review and meta-analysisManaging type 2 diabetes: balancing HbA1c and body weight.Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.Acarbose monotherapy and weight loss in Eastern and Western populations with hyperglycaemia: an ethnicity-specific meta-analysis.Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.Meta-analysis and critical review on the efficacy and safety of alpha glucosidase inhibitors in Asian and non-Asian populations.Acarbose: its role in the treatment of diabetes mellitus.Non-insulin dependent diabetes in children and adolescents: the therapeutic challenge.Effects of chronic treatment with acarbose on glucose and lipid metabolism in obese diabetic Wistar rats.Effect of acarbose on weight maintenance after dietary weight loss in obese subjects.Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters.The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes.The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study.Synthesis of alpha-mannosylated phenolics as alpha-glucosidase inhibitors.Screening and structural characterization of alpha-glucosidase inhibitors from hawthorn leaf flavonoids extract by ultrafiltration LC-DAD-MS(n) and SORI-CID FTICR MS.Effect of energy-reduced diets high in dairy products and fiber on weight loss in obese adults.Utility of a short-term 25% carbohydrate diet on improving glycemic control in type 2 diabetes mellitus.Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database.Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.Acarbose vs. bedtime NPH insulin in the treatment of secondary failures to sulphonylurea-metformin therapy in type 2 diabetes mellitus.Acarbose treatment does not change the habitual diet of patients with Type 2 diabetes mellitus. The Finnish Acargbos Study Group.Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy.Sulfonylurea treatment in type 2 diabetes.GLP-1: target for a new class of antidiabetic agents?Medications that cause weight gain and alternatives in Canada: a narrative review
P2860
Q24186660-8B6DD284-92B0-4B9F-8C41-6AB875EBAA11Q24197884-BBEE27E0-23D0-46BF-909C-77A1501914BEQ24246908-14803E76-CBEB-4FE7-B25B-8A6F572742A1Q33442343-8DCBC902-15C4-4C4F-A410-EA4B0FB6E9DBQ33985182-B83189D6-13DD-4CE8-AC1C-00233305AB45Q34163110-18D48D96-6803-4878-8CD6-3F5A156501CBQ34549886-1A1FC85D-C1E6-4FC0-962D-DC63168DF99EQ35823982-E89B925F-50CC-4434-BDEC-98825B093AF5Q36299039-345F1D62-E1ED-4E4C-B06A-E7B63C6FC3D2Q36333089-6FD9AE9E-A640-410D-B6AF-5A14501FF0F7Q37232678-FF0B6CA0-6564-4583-AB3B-E814C3D49A6EQ37750274-B28DF2E1-59D1-46BB-86AC-B6F52EB33749Q38038097-078EA0D3-5695-422F-AB8D-87D1626FA469Q38213904-BF7ECEDE-51A5-49F6-996F-F19C985FE199Q38563239-EA23D53B-AF70-4174-AC2D-E599128DA074Q39420555-221DD540-DD76-47F9-A9EE-6589FED45FEEQ41206503-AEE5A83C-6B57-4D0F-854F-C79B5F118C72Q41716386-46E94D3B-1B32-4545-B9FA-97B633EB5E38Q43718269-84E5E519-AD58-4F59-8263-4009D4545F7AQ43923307-6366B389-E9E5-4CF1-83F7-2F9F46A32D59Q44107437-AE31E574-D285-4BEC-A966-F6AFFD85B856Q44111090-94244D01-7BEC-4F04-8CF4-B9983F8D62D3Q44393961-D12EB7AE-7B51-4285-A5DC-C153A6570700Q44700368-06FD5C0E-6AD9-4CC8-B344-26522B296834Q45079114-E7D086EA-A6B4-4F28-9D1A-8513B1DDF00DQ46011577-17256A51-DB9E-4505-AABF-8557A4FBC4FEQ46675939-50ED6DB7-7B85-43EF-9C91-8FE8D399DDA5Q46724052-CC53E6A9-06D4-432E-B4C1-37B537220109Q46783489-2C5D4E3E-8F80-4EEA-BFC6-34266D367163Q51278212-E360CD08-2D68-4A07-A3CC-3C81EC7880D1Q51550685-90498C52-8237-47EB-9C36-6EE34CE55416Q51558092-E76153BC-F130-4075-86ED-D1A566E36D05Q54017862-51610BA2-D083-4E1D-8521-7B9CAA3D6BE3Q55048382-2D87F912-0FB2-46A5-81C9-38CDF4C23E1AQ55116155-F4AB2D78-C6B4-4A54-B70C-37B5AD5C036AQ58729864-B1AB3F54-4029-488A-89E7-32612AE5461A
P2860
Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.
description
1995 nî lūn-bûn
@nan
1995 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Multicenter, placebo-controlle ...... n-dependent diabetes mellitus.
@ast
Multicenter, placebo-controlle ...... n-dependent diabetes mellitus.
@en
type
label
Multicenter, placebo-controlle ...... n-dependent diabetes mellitus.
@ast
Multicenter, placebo-controlle ...... n-dependent diabetes mellitus.
@en
prefLabel
Multicenter, placebo-controlle ...... n-dependent diabetes mellitus.
@ast
Multicenter, placebo-controlle ...... n-dependent diabetes mellitus.
@en
P2093
P921
P1476
Multicenter, placebo-controlle ...... n-dependent diabetes mellitus.
@en
P2093
P304
P356
10.1016/S0002-9343(99)80343-X
P407
P577
1995-05-01T00:00:00Z